Get the Stockscreener App
0.3871
3.20%
-0.0128
Cytosorbents Corp stock is traded at $0.3871, with a volume of 42,067.
It is down -3.20% in the last 24 hours and up +7.53% over the past month.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
See More
Previous Close:
$0.3999
Open:
$0.4
24h Volume:
42,067
Relative Volume:
0.28
Market Cap:
$24.45M
Revenue:
$37.20M
Net Income/Loss:
$-11.85M
P/E Ratio:
-2.0288
EPS:
-0.1908
Net Cash Flow:
$-10.59M
1W Performance:
+6.93%
1M Performance:
+7.53%
6M Performance:
-39.53%
1Y Performance:
-66.63%
1-Day Range:
$0.3891
$0.40
1-Week Range:
$0.36
$0.40
52-Week Range:
$0.35
$1.1882
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.3891 | 25.13M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
110.05 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.95 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.59 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.51 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.72 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat - Investing.com
Cytosorbents : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Cytosorbents Corp reports results for the quarter ended June 30Earnings Summary - TradingView
CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue - TradingKey
CytoSorbents: Q2 Earnings Snapshot - marketscreener.com
Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary - TradingView
Cytosorbents Corp. R (HQE1.DU) Q2 FY2026 earnings call transcript - Yahoo Finance
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire
CytoSorbents (Nasdaq: CTSO) flags going concern as cash falls to $5.9M - Stock Titan
Cytosorbents Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021 - TradingKey
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45PCR Mean Reversion - dars.gov.et
Cytosorbents CFO Peter Mariani buys $44,000 in stock - Investing.com UK
Cytosorbents CFO Peter Mariani buys $44,000 in stock By Investing.com - Investing.com India
Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market - Stock Titan
Cytosorbents CEO Phillip Chan buys $104,897 in company stock - Investing.com
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytosorbents Corp Stock (CTSO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):